APPLAUSE-IgAN is a phase 3, randomized double-blind, placebo-controlled trial that included patients with biopsy-confirmed IgAN and proteinuria of at least 1 g\/g (n=477), despite supportive care. Patients randomly received (1:1) iptacopan 200 mg or placebo twice a day for 24 months and continued to receive supportive treatment.<\/p>\n
The exploratory end points of the trial included changes from baseline in complement biomarkers, such as urinary sC5b-9, serum Wieslab activity, C3, and C4. Researchers also evaluated the changes in galactose-deficient IgA1 (Gd-IgA1) and urinary sCD163 in the interim analysis population at month 9.<\/p>\n
At month 24, researchers observed a reduction in Wieslab activity and urinary sC5b-9 and increased serum C3 after treatment with iptacopan. C4 levels were unchanged and were consistent with the findings from month 9. In addition, in the iptacopan arm, levels of Gd-IgA1 remained unchanged from baseline. The reduction in sCD163 from baseline was greater in the iptacopan arm than in the placebo arm.<\/p>\n
\u201cSustained modulation of complement biomarkers at M9 [month 9] and M24 [month 24] indicates that iptacopan selectively and durably inhibits the AP. As expected from iptacopan\u2019s proposed mechanism of action, Gd-IgA1 was not affected,\u201d the researchers concluded. \u201cThe reduction in urinary sCD163 suggests that iptacopan also attenuates glomerular inflammation in patients with IgAN.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"APPLAUSE-IgAN is a phase 3, randomized double-blind, placebo-controlled trial that included patients with biopsy-confirmed IgAN and proteinuria of…\n","protected":false},"author":2,"featured_media":665824,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-665823","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/665823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=665823"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/665823\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/665824"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=665823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=665823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=665823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}